No Data
No Data
Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
Aligos Therapeutics Announces Chief Medical Officer Resignation
Why Investors Shouldn't Be Surprised By Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 26% Share Price Plunge
The Aligos Therapeutics, Inc. (NASDAQ:ALGS) share price has softened a substantial 26% over the previous 30 days, handing back much of the gains the stock has made lately. The drop over the last 30
Aligos Therapeutics Reports Q1 Results
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 58.49 percent increase over losses o